Menu
← Oncology Approval Tracker
FDA DECISION ·
Nilotinib capsules (later Nilecya)
nilotinib · Cipla
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with newly diagnosed chronic-phase Philadelphia chromosome-positive CML, or chronic- or accelerated-phase disease resistant or intolerant to previous treatment that included imatinib.
LAMPGEN ANALYSIS
Why it matters
This original 505(b)(2) approval adds a separately approved nilotinib capsule product with adult CML indications.
What research teams should watch
Verify the exact capsule product and fasted administration instructions; maintain ECG, electrolyte, and interaction checks.
PRIMARY RECORDS